News

bit.bio receives £40m of backing for technology that it claims can reliably reprogram stem cells.

Mark Kotter Bit Bio ideaSpace, focus on a founder, celebrating 10 years of idea space.

The investors behind Bit Bio's series A fundraise.

Bit Bio raises series A funding for its programming approach to human cells.

Discovery Drive-based synthetic biology Bit Bio has closed a $41.5million Series A investment.

Paul Morril, Horizon Discovery co-founder joins as CBO and Florian Schuster, Tessa Therapeutics, as CFO.

bit.bio combines the concepts of coding and biology to provide human cells for research, drug discovery and cell therapy.

Reprogramming human cells by bit.bio.